Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncobiologics ONSI.W

Healthcare Biotechnology

Recent & Breaking News (NDAQ:ONSI.W)

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire December 1, 2020

Outlook Therapeutics Announces Creation of Global Retina Advisory Council

GlobeNewswire November 19, 2020

Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA(TM)

GlobeNewswire November 11, 2020

Outlook Therapeutics Secures $10 Million in Additional Working Capital

GlobeNewswire November 5, 2020

Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA(TM) (bevacizumab-vikg)

GlobeNewswire November 3, 2020

Outlook Therapeutics to Present at the Virtual Investor KOL Roundtable

GlobeNewswire October 22, 2020

Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg)

GlobeNewswire October 13, 2020

Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital

GlobeNewswire October 7, 2020

Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration

GlobeNewswire September 30, 2020

Outlook Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire September 8, 2020

Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg) from NORSE 1

GlobeNewswire August 26, 2020

Outlook Therapeutics Reports Financial Results for the Third Quarter of Fiscal Year 2020 and Provides Corporate Update

GlobeNewswire August 14, 2020

Outlook Therapeutics Announces Closing of $1.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire July 17, 2020

Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg)

GlobeNewswire July 7, 2020

Outlook Therapeutics Announces Closing of $10.2 Million Financing Priced At-The-Market Under Nasdaq Rules

GlobeNewswire June 25, 2020

Outlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq Rules

GlobeNewswire June 23, 2020

Outlook Therapeutics Provides Clinical Update on ONS-5010 / LYTENAVA(TM) (bevacizumab-vikg)

GlobeNewswire June 17, 2020

Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire June 11, 2020

Outlook Therapeutics to Present at the Virtual Investor Fireside Chat Series

GlobeNewswire June 9, 2020

Outlook Therapeutics Announces Closing of $16.0 Million Private Placement

GlobeNewswire June 3, 2020